<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33638898</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1253</StartPage><EndPage>1256</EndPage><MedlinePgn>1253-1256</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15348</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IUIN, CIBERNED and IRYCIS, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>IUIN, CIBERNED and IRYCIS, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cueto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IUIN, CIBERNED and IRYCIS, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Mar&#xed;a A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Centro Nacional de Investigaciones Cardiovasculares (CNIC), Instituto de Salud Carlos III, IUIN and I+12, Departamento de Farmacolog&#xed;a y Toxicolog&#xed;a, Facultad de Medicina, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Br J Pharmacol. 2021 May;178(10):2162</RefSource><PMID Version="1">33932232</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>27</Day><Hour>12</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33638898</ArticleId><ArticleId IdType="doi">10.1111/bph.15348</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Buratti, E. (2020). Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. British Journal of Pharmacology, 178, 1298-1315. https://doi.org/10.1111/bph.15148</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz, J. (2019). The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. British Journal of Pharmacology, 176, 1370-1383. https://doi.org/10.1111/bph.14382</Citation></Reference><Reference><Citation>Herrando-Grabulosa, M., Gaja-Capdevila, N., Vela, J. M., &amp; Navarro, X. (2020). Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis. British Journal of Pharmacology, 178, 1336-1352. https://doi.org/10.1111/bph.15224</Citation></Reference><Reference><Citation>Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., &amp; Gitler, A. D. (2020). ALS genetics: Gains, losses, and implications for future therapies. Neuron, 108, 822-842. https://doi.org/10.1016/j.neuron.2020.08.022</Citation></Reference><Reference><Citation>Klingl, Y. E., Pakravan, D., &amp; Van Den Bosch, L. (2020). Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis. British Journal of Pharmacology, 178, 1353-1372. https://doi.org/10.1111/bph.15217</Citation></Reference><Reference><Citation>Manzano, R., Toivonen, J. M., Moreno-Mart&#xed;nez, L., de la Torre, M., Moreno-Garc&#xed;a, L., L&#xf3;pez-Royo, T., &#x2026; Osta, R. (2020). What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy. British Journal of Pharmacology, 178, 1279-1297. https://doi.org/10.1111/bph.15276</Citation></Reference><Reference><Citation>Palomo, V., Nozal, V., Rojas-Prats, E., Gil, C., &amp; Martinez, A. (2020). Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 178, 1316-1335. https://doi.org/10.1111/bph.15221</Citation></Reference><Reference><Citation>Riancho, J., Delgado-Alvarado, M., Andreu, M. D., Paz-Fajardo, L., Arozamena, S., Gil-Bea, F. J., &amp; L&#xf3;pez de Muna&#xed;n, A. (2020). Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge. British Journal of Pharmacology, 178, 1269-1278. https://doi.org/10.1111/bph.15151</Citation></Reference><Reference><Citation>Riancho, J., Paz-Fajardo, L., &amp; L&#xf3;pez de Muna&#xed;n, A. (2020). Clinical and preclinical evidence of somatosensory involvement in amyotrophic lateral sclerosis. British Journal of Pharmacology, 178, 1257-1268. https://doi.org/10.1111/bph.15202</Citation></Reference><Reference><Citation>Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H., Gordon, J. W. (1995). Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis.. Proceedings of the National Academy of Sciences, 92(3), 689-693. https://doi.org/10.1073/pnas.92.3.689</Citation></Reference><Reference><Citation>Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., &#x2026; Rahmani, Z. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362, 59-62. https://doi.org/10.1038/362059a0</Citation></Reference><Reference><Citation>Van Damme, P., Robberecht, W., Van Den Bosch, L. (2017). Modelling amyotrophic lateral sclerosis: progress and possibilities. Disease Models &amp; Mechanisms, 10, 537-549. https://doi.org/10.1242/dmm.029058</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>